Search results

118 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter
Public health guidelines Remove Public health guidelines filter

LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amivantamab for non-small cell lung cancer [ID3836]

Proposed [GID-TA10729] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]

Proposed [GID-TA10658] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Proposed [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Proposed [GID-TA10666] Expected publication date: 26 August 2021

Type

Technology appraisal guidance

Status

Proposed
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Proposed [GID-TA10676] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Proposed [GID-TA10763] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Proposed [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Proposed [GID-TA10764] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for managing overweight and obesity [ID3850]

Proposed [GID-TA10765] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Proposed [GID-TA10733] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]

Proposed [GID-TA10782] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed

Filter (6 in use)

Type 1 selected

Status 1 selected

Last updated

Guidance programme 4 selected

118 results

LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Amivantamab for non-small cell lung cancer [ID3836]

177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Cabotegravir and rilpivirine for treating HIV-1 [ID3766]

Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Liposomal bupivacaine for treating postoperative pain [ID3799]

Semaglutide for managing overweight and obesity [ID3850]

Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]